Bopindolol is an orally active antagonist of beta-adrenoceptors (ARs) with partial agonist activity. Bopindolol is non-selective for beta1- and beta2-ARs and has low affinity for beta3-AR subtype. Bopindolol is a prodrug of pindolol and can be rapidly metabolized to an active hydrolyzed form. Bopindolol can be used for essential and renovascular hypertension research [1] [2].
